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We certainly appreciate the positive comments by Sansom1
regarding the value of our study2 in demonstrating a clear
role for maxi-K channels in renal K transport in the distal
convoluted tubule. We obviously agree with Sansom that
our study leaves little doubt that maxi-K channels can
contribute to distal K secretion and renal K excretion,
especially following adaptation to a high K diet.
K excretion and hypokalemia in individuals with Type
II Bartter’s syndrome associated with ROMK mutations is
much less severe than in other types of hyperprostaglandin
E syndrome where both ROMK and maxi-K channels can
contribute to K wasting. The FEK of 158% stated by
Sansom was from the original ROMK null mouse that
exhibited marked hydronephrosis.3 The Romk/ mouse
used in our study reported in Kidney International2 was
developed from intercrossing null males for 45 genera-
tions to select for high postnatal survival and less
hydronephrosis. Clearance results in our Romk/ mice
indicate that FEK is B50% under control diet conditions
which is more in line with the less severe K wasting
expected in the absence of ROMK (full details will be
reported in a future publication). Thus, a highly exagger-
ated K secretion in the distal tubule is not a prerequisite
for the K excretion observed in our Romk/ mice.
In our paper, we proposed that decreased K reabsorp-
tion by the loop of Henle as well as continued K secretion
via maxi-K channels in the distal convoluted tubule (DCT)
contributed to the kaluresis in the ROMK knockout
animal. The former mechanism for enhanced K excretion
in Romk/ mice was based on the experimental observa-
tion of an increased free-flow K concentration in early
DCT fluid in ROMK knockout, compared to wild-type,
mice. The primary issue raised by Sansom was our
interpretation of this elevated K concentration. Our
conclusion of diminished K reabsorption in the thick
ascending limb (TAL) stems from previous in vivo
micropuncture–microperfusion studies by us4 and others.5
in vivo studies reveal no significant K secretion in the early
DCT measured under free-flow and perfusion condi-
tions.4,5 Is it possible that the high early distal tubule
fluid flow in the Romk/ mice activated maxi-K channels
that were quiescent in wild-type animals? We think not
because latter in vivo studies showed that K secretion in
the early DCT was not clearly changed by adaptation to a
high K diet or to increased tubule flow rate. In contrast,
both maneuvers greatly increased K secretion in the late
DCT, the region where we performed the stationary
microperfusion experiments that revealed the iberiotoxin-
sensitive K secretory pathway in Romk/ mice. Given the
results from these in vivo studies, it is problematic to
invoke K secretion via maxi-K channels as an alternative
mechanism to account for the increased free-flow K
concentration observed in the early DCT fluid from
Romk/ mice.2
In addition, as we discussed in our paper, the in vivo
experiments by Walter et al.6 using 5 mM barium as a K
channel blocker should not be used as a strong argument
against the role of apical K channel activity as a
requirement for TAL function including net K reabsorp-
tion. This is based on our previous study in mouse TAL
where a much high concentration of barium (about 20 mM)
was required to achieve a nearly complete block of the
apical K conductance in the absence of luminal potassium.7
In addition, it is virtually impossible to eliminate K
completely from the tubule fluid at the TAL in the
in vivo setting and the presence of luminal K will
reduce the blocking effect of barium. Thus, the ROMK
KO animal provides the only model we are aware of for
analyzing the effect of the absence of apical K channel
activity (both 35 and 70 pS channels) on K reabsorption
in the TAL.8,9
Regarding the proposed model by Sansom for potas-
sium transport in the absence of apical K conductance, we
would like to make the following comment. Key factors
required for any remaining K reabsorption by the TAL are
the functional activity of apical Na–K–2Cl cotransporter,
the basolateral Cl channel and the intracellular Cl
activity. These transporters are under complex regulation
and their activities cannot be deduced with certainty in the
condition where there is no apical ionic conductance,
basolateral membrane is depolarized and the transcellular–
paracellular current circuit is disrupted. Ultimately, this
issue may only be resolved by measuring tracer rubidium
fluxes in the isolated perfused TAL preparation from
Romk/ mice.
In conclusion, the lack of significant K secretion in the
early DCT in vivo, even under circumstances that would
highly activate maxi-K channels, suggests that the most
likely explanation for the increased K concentration in
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early distal tubule fluid is not K secretion at the early DCT,
but rather a reduction in K reabsorption in the TAL.
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Parathyroid hormone synthesis
suppression by 25(OH)2 vit D3
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To the Editor: The recent in vitro studies of the Slatopolsky
group1 have shown that the ‘non active’ 25-OH-vitamin D
metabolite was actually efficient (even though less potent) at
physiological concentration for suppressing parathyroid
hormone synthesis by direct stimulation of the vitamin D
receptor, and that this direct stimulation was even pre-
ponderant over that induced by 1,25(OH) vitamin D3
produced in situ. This is consistent with our earlier reports
evidencing (1) in predialysis patients,2 a good long-term
control of hyperparathyroid bone disease by just normocal-
cemic dose of 25-OH-vitamin D in association with up to
2.4 g/day of CaCO3 and (2) in dialysis patients,
3 an
independent inverse link between parathyroid hormone and
25-OH-vitamin D serum concentrations independently of
serum concentrations of calcitriol, calcium, and phosphate.
This challenges the NKF-K/DOQI recommendation for
suppressing intact parathyroid hormone 4300 pg/ml in
dialysis patients, to inject hypercalcemic and hyperpho-
sphatemic dose of calcitriol and paricalcitol, instead of
correcting the highly prevalent (87%) vitamin D deficiency in
American patients. This correction would decrease the need
of ‘active’ vitamin D derivatives for this suppression, while
better preventing vascular calcification (in spite of concomi-
tant use of calcium–phosphate binder) as suggested by the
comparison of the two cohorts of young adults with
childhood-onset of end-stage renal disease, as quoted in
our letter to Kidney International about Kalantar-Zadeh
article,4 pointing out that the survival benefit granted by
paricalcitol was inversely related to its dose.
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The letter from Shahapuni et al.1 cites our finding that
25-hydroxyvitamin D3 (25(OH)D3) suppresses parathyroid
hormone (PTH) synthesis in cultured parathyroid cells2 to
emphasize earlier studies from their group (1) demonstrat-
ing the skeletal benefits of improving vitamin D status in
chronic kidney disease patients, and (2) the inverse
correlation of PTH with 25(OH)D3 but not with calcitriol
in dialysis patients, relationships that have also been
documented in the general population.3
In response, we feel it necessary to clarify two points in
the letter. First, the authors incorrectly state that our data
showed that 25(OH)D3 produced a greater decrease in PTH
than calcitriol. In fact, the maximal reduction in both PTH
secretion and PTH mRNA was not different. Second, the K/
DOQI guidelines do not recommend injecting hypercalce-
mic or hyperphosphatemic doses of calcitriol or its analogs
as stated in the letter. The algorithms clearly state the
target ranges for plasma Ca and P and suggest modifica-
tions when they are exceeded.
The K/DOQI guidelines recommend ergocalciferol
supplementation in predialysis patients with 25(OH)D3
levels less than 30 ng/ ml, but as Shahapuni et al. point out,
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